Kin Meds review

What it is

Kin Meds is a LegitScript-certified telehealth platform selling weight-loss and longevity care on one account. Its wellness line runs sermorelin injections and sermorelin troches, NAD⁺ injections, NAD⁺ nasal spray and NAD⁺ troches, glutathione, a glutathione nasal spray and a GHK-Cu face cream; its men's health line adds PT-141 injection and nasal spray, TriMix, oxytocin and tadalafil; its hormone line adds estradiol and progesterone. The GLP-1 side carries both compounded semaglutide and tirzepatide and brand-name Wegovy, Zepbound and Foundayo. It describes itself as a patient-management platform partnering with independent licensed physician networks rather than a pharmacy or prescriber.

How it works

Asynchronous and platform-mediated: you complete a questionnaire, an independent licensed provider reviews it, and if a prescription is issued an unnamed third-party licensed pharmacy dispenses and ships it, with each wellness product sold as a 30-day supply shipped every 30 days. Free shipping in one to four days is stated, and products are marked HSA/FSA eligible. Two structural things are worth knowing before you start. First, the whole wellness line carries an availability notice that it is not currently available to patients located in California because of state and pharmacy restrictions, and the site says availability may change as pharmacy coverage updates — so a Californian reader can stop here. Second, the entity questions are unusual in number: the terms disclose no LLC or corporation, the governing law is Georgia while arbitration is set in San Diego, the privacy policy lists a Manhattan Beach, California address while the footer lists Columbia, Maryland, and the footer credits the site to a marketing agency. LegitScript certification is displayed and is a real check on the pharmacy-and-advertising side, but it does not tell you who owns the business.

Pricing transparency

This is Kin Meds at its best. Sermorelin injections start at $349 for a 30-day supply, NAD⁺ injections at $249, the NAD⁺ nasal spray at $349, glutathione at $249 and the GHK-Cu face cream at $199 — each stated on its own product page rather than quoted after an intake. Read "starts at" literally: these are entry figures for a personalised prescription, so ask whether the number moves when a provider sets your dose. Two of the wellness products we checked, glutathione and the testosterone line, showed "Coming Soon" in place of a start button, so confirm a product is actually orderable before planning around it. On the GLP-1 side, compounded semaglutide starts at $199/mo and tirzepatide at $249/mo, and the "from $149/mo" brand pricing is an insured or savings-card entry tier — cash-pay patients going through NovoCare or LillyDirect should expect materially more. None of that is a peptide price and none of it should be read as one.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Kin Meds states plainly that compounded medications have not been evaluated or approved by the FDA for safety, efficacy or quality — clearer than several competitors — but it is not itself a pharmacy and does not name the third-party pharmacy that dispenses, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On evidence, the wellness menu is not one thing. Sermorelin is a GHRH analogue that stimulates your own pituitary, a real and well-described mechanism whose long-term human outcome data remains thin; the troche form has less pharmacokinetic support than the injection. Injected, intranasal and sublingual NAD⁺ have no controlled human outcome trials — the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly — while oral NR and NMN reliably raise blood NAD⁺, a raised biomarker rather than a demonstrated benefit. Glutathione and GHK-Cu have essentially no controlled human outcome data. PT-141 (bremelanotide) is the outlier in the other direction: the injectable is an FDA-approved drug for one narrow indication, generalised hypoactive sexual desire disorder in premenopausal women, and a compounded version prescribed to anyone else is off-label use of an approved molecule. Individual results vary.

Pros and watch-outs

The evidence behind what Kin Meds prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

• GHK-Cu: the copper peptide between real skincare and overclaim

  A decades-deep molecule with a credible topical story — and systemic anti-aging claims that outrun the human data.

• PT-141 (bremelanotide): the evidence on a research-popular peptide that is actually FDA-approved

  Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women, with phase-3 trial evidence. A straight read of what's proven — and where off-label use goes beyond it.

How Kin Meds compares

A few alternatives worth a look, depending on what you’re optimizing for.

• KOKongo

  NAD⁺ injections at a published flat rate across all 50 states

  See Kongo →
• LRLevelUp Rx

  NAD⁺ injections from a platform that names the pharmacies dispensing them

  See LevelUp Rx →
• LMLaSara Medical Group

  NAD⁺ buyers who want the concentration and vial size stated, not just a monthly price

  See LaSara Medical Group →